WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Wendy L. Devine
Partner
Litigation
San Francisco
wdevine@wsgr.com

D415-947-2027

Download vCard
Open PDF
  • Leader of the Patent Litigation Practice Group

    Wendy is co-chair of the firm's patent litigation practice group and represents clients in cutting-edge patent and IP-related disputes.

  • Experienced Litigator

    Wendy has represented clients in litigations in several jurisdictions in matters involving various technologies and processes, including biotechnology, biosimilars, pharmaceuticals, food science, medical devices, medical methods, trademarks, and trade secrets. She has significant experience in Hatch-Waxman patent litigation and related client counseling, including pre-litigation strategy.

Wendy Lynn Devine serves as co-chair for the patent litigation team and focuses her practice on intellectual property litigation with a concentration in patent litigation and counseling. Leveraging the combination of her significant legal and scientific skills, she has successfully counseled and represented clients in matters involving various technologies and processes, including biotechnology, biosimilars, pharmaceuticals, food science, medical devices, medical methods, trademarks, and trade secrets. Her clients rely on her deep experience and ability to quickly grasp complex and cutting-edge issues. Her diverse industry and scientific subject matter experience informs her ability to foster highly productive collaborations within a client’s key functions, from scientists and product developers to senior executives and board members.

Wendy has significant experience in Hatch-Waxman patent litigation and related client counseling from advising on a complaint or drafting key briefs in high-stakes trial court matters to devising long-term strategies for crafting test cases designed to shape the law. Pharmaceutical patent litigation is a key part of balancing research and innovation with access to affordable medications, and Wendy’s work for prominent companies on both sides is extensive. She has represented clients in litigations in several jurisdictions, including the United States Court of Appeal for the Federal Circuit, Southern, Northern, and Central Districts of California, District of Delaware, Northern District of Illinois, District of New Jersey, Southern District of New York, Eastern District of North Carolina, Eastern District of Texas, Northern District of West Virginia, and the San Diego Superior Court. She routinely argues motions and examines fact and expert witnesses, both in deposition and at trial. Wendy is recognized as a top Hatch-Waxman litigator by Patexia based on activity and performance.

Prior to joining the firm in 2006, Wendy acquired an extensive scientific background at the University of California, Davis. Her work included laboratory research focused on high-performance liquid chromatography (HPLC), genetic sequencing, animal husbandry, histology, and physiology. Wendy maintains a strong interest in working with her clients in the area of agricultural sciences.

Wendy serves in multiple leadership roles including serving as the litigation hiring partner for the firm. In addition, she is a strong advocate for and participant in the firm’s pro bono legal program and has been recognized for her advocacy. She is also an active attendee and participant in the firm’s biennial Women’s Leadership Summit, an event designed to build attendees’ leadership, mentoring, and relationship skills and encourage them to implement the best strategies to grow and enhance their careers.

Experience

Wendy Lynn Devine serves as co-chair for the patent litigation team and focuses her practice on intellectual property litigation with a concentration in patent litigation and counseling. Leveraging the combination of her significant legal and scientific skills, she has successfully counseled and represented clients in matters involving various technologies and processes, including biotechnology, biosimilars, pharmaceuticals, food science, medical devices, medical methods, trademarks, and trade secrets. Her clients rely on her deep experience and ability to quickly grasp complex and cutting-edge issues. Her diverse industry and scientific subject matter experience informs her ability to foster highly productive collaborations within a client’s key functions, from scientists and product developers to senior executives and board members.

Wendy has significant experience in Hatch-Waxman patent litigation and related client counseling from advising on a complaint or drafting key briefs in high-stakes trial court matters to devising long-term strategies for crafting test cases designed to shape the law. Pharmaceutical patent litigation is a key part of balancing research and innovation with access to affordable medications, and Wendy’s work for prominent companies on both sides is extensive. She has represented clients in litigations in several jurisdictions, including the United States Court of Appeal for the Federal Circuit, Southern, Northern, and Central Districts of California, District of Delaware, Northern District of Illinois, District of New Jersey, Southern District of New York, Eastern District of North Carolina, Eastern District of Texas, Northern District of West Virginia, and the San Diego Superior Court. She routinely argues motions and examines fact and expert witnesses, both in deposition and at trial. Wendy is recognized as a top Hatch-Waxman litigator by Patexia based on activity and performance.

Prior to joining the firm in 2006, Wendy acquired an extensive scientific background at the University of California, Davis. Her work included laboratory research focused on high-performance liquid chromatography (HPLC), genetic sequencing, animal husbandry, histology, and physiology. Wendy maintains a strong interest in working with her clients in the area of agricultural sciences.

Wendy serves in multiple leadership roles including serving as the litigation hiring partner for the firm. In addition, she is a strong advocate for and participant in the firm’s pro bono legal program and has been recognized for her advocacy. She is also an active attendee and participant in the firm’s biennial Women’s Leadership Summit, an event designed to build attendees’ leadership, mentoring, and relationship skills and encourage them to implement the best strategies to grow and enhance their careers.

Education
  • J.D., University of San Diego School of Law
  • M.S., Animal Science, University of California, DavisEmphasis in Genetics
  • B.S., Animal Science, University of California, Davis
Honors
  • Named among Lawdragon’s "500 Leading Global IP Lawyers," 2025-2026
  • Named among Lawdragon’s "500 Leading Litigators in America," 2025-2026
  • Named among the 2024 and 2025 “Top Intellectual Property Lawyers” by the Daily Journal
  • Recognized for her expertise in Hatch-Waxman litigation in the WIPR USA Patents 2024 guide, where the firm is ranked as a “Recommended” firm
  • Recognized by Patexia as one of the best performing ANDA attorneys and most active practitioners for representing plaintiffs and defendants in its 2023 ANDA Litigation Intelligence Report
  • WSGR John Wilson Award for pro bono service, 2011-2012
  • Wiley W. Manuel Award for Pro Bono Legal Services (State Bar of California; 2009, 2012)
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., University of San Diego School of Law
  • M.S., Animal Science, University of California, DavisEmphasis in Genetics
  • B.S., Animal Science, University of California, Davis
Honors
  • Named among Lawdragon’s "500 Leading Global IP Lawyers," 2025-2026
  • Named among Lawdragon’s "500 Leading Litigators in America," 2025-2026
  • Named among the 2024 and 2025 “Top Intellectual Property Lawyers” by the Daily Journal
  • Recognized for her expertise in Hatch-Waxman litigation in the WIPR USA Patents 2024 guide, where the firm is ranked as a “Recommended” firm
  • Recognized by Patexia as one of the best performing ANDA attorneys and most active practitioners for representing plaintiffs and defendants in its 2023 ANDA Litigation Intelligence Report
  • WSGR John Wilson Award for pro bono service, 2011-2012
  • Wiley W. Manuel Award for Pro Bono Legal Services (State Bar of California; 2009, 2012)
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office

Select Matters

Wendy and her team have secured strategic wins in recent years for clients across the life sciences industry. Some recent examples include:

  • Represented Mylan Pharmaceuticals Inc. in a successful appeal at the U.S. Court of Appeals affirming a decision by the Patent Trial and Appeal Board that held key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan in both the challenge before the PTAB and at the Federal Circuit.
  • Representing Azurity Pharmaceuticals in patent litigation against Alkem defending Azurity’s intellectual property related to its Zonisade® product. (District of Delaware)
  • Representing Bow River LLC in Hatch-Waxman patent litigation against Alembic defending Bow River’s intellectual property rights. (District of Delaware)
  • Representing Azurity Pharmaceuticals in patent litigation against Saba defending Azurity’s intellectual property related to its Edarbyclor® product. (District of Delaware)
  • Served as lead counsel for Impossible Foods in a patent infringement litigation alleging infringement of seven Impossible Foods patents covering manufacturing processes, ingredients, and finished products relating to plant-based food containing heme and Impossible’s innovative transgenic yeast used to manufacture that heme. Successfully represented Impossible Foods in defense of six inter partes review petitions before the Patent Trial and Appeal Board in 2022 and 2023. Defeated defendant’s motion to dismiss and motion to stay the district court litigation. The matter was closely watched as the first patent infringement case in the burgeoning foodtech industry. With trial approaching, the parties resolved the matter and released a joint statement that said: “This resolution affirms Impossible Foods’ category leadership and the strength of its product portfolio related to heme.”  
  • Secured a dismissal for Spruce Biosciences in declaratory judgement litigation related to treatments for congenital adrenal hyperplasia (CAH) in a suit filed by Neurocrine Biosciences. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation against Amneal defending Azurity’s intellectual property related to its Nymalize® product. The matter settled favorably prior to trial. (District of New Jersey)
  • Representing Sandoz Inc. in patent infringement litigation relating to Sandoz’s generic version of Esbriet®. (District of New Jersey)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s generic version of Trulance®. (Northern District of West Virginia)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s generic version of Cinvanti®. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Thyquidity® product. The matter settled favorably. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Eprontia® product. The matter settled favorably. (District of New Jersey)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Katerzia® product. The matter settled favorably on the eve of trial. (District of New Jersey)
  • Represented Mylan Pharmaceuticals Inc. in proceedings which limited where Hatch-Waxman Act patent suits over generic drugs can be filed, rejecting an argument that the suits are permitted wherever the generic product may one day be sold. Instead, the court ruled that suit can be brought only in locations that are related to the generics maker’s filing of an abbreviated new drug application (ANDA). The Federal Circuit issued a unanimous, precedential opinion and backed a federal judge’s ruling that tossed on venue grounds Valeant Pharmaceuticals and Kaken Pharmaceutical Co. Ltd.’s infringement case against our client over competing versions of an antifungal medication, Jublia.
  • Represented Azurity Pharmaceuticals in patent litigations defending Azurity’s intellectual property related to its Firvanq® product. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigations defending Azurity’s intellectual property related to its Epaned® ready-to-use product. (District of Delaware)
  • Represented Thorne Research, Inc. in a patent litigation involving accusations by ChromaDex, Inc. and the Trustees of Dartmouth College that certain Thorne nutritional supplement products infringed their patents. Secured dismissal following invalidation of the asserted patents.  (Southern District of New York)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s a generic version of Restasis®. Following bench trial, the court held all asserted patent claims invalid. (Eastern District of Texas)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Qbrelis® product. (District of Delaware and District of New Jersey)
  • Represented Azurity Pharmaceuticals in a Hatch-Waxman patent infringement litigation relating to Azurity’s generic version of Januvia® (sitagliptin). The case was dismissed. (District of Delaware)
  • Represented Silvergate Pharmaceuticals, Inc. in Hatch-Waxman litigation defending Silvergate’s intellectual property related to its Epaned Kit® powder for oral solution product. The matter concluded with favorable settlement. (District of Delaware)
  • Successfully defended Mylan Technologies, Inc. against a motion for restraining order/preliminary injunction involving a Mylan’s generic version of Minivelle®, a transdermal product, with the court’s written opinion holding in favor of Mylan client on case dispositive issues. (District of Delaware)
  • Represented Pfenex, a biotechnology company, in inter partes review (IPR) proceedings challenging vaccine production patents owned by GlaxoSmithKline Biologicals SA. Took and defended expert depositions and delivered oral arguments resulting in a favorable settlement on the eve of the issuance of a PTAB decision.
  • Represented NuVasive, Inc., a medical device manufacturer, in patent infringement litigation against a competitor that marketed devices accused of infringing NuVasive’s patents for its groundbreaking spine fusion device. (Southern District of California)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s a generic version of Jevtana. Following bench trial, the court held the asserted claims of the later-expiring patent invalid. (District of New Jersey)
Matters

Select Matters

Wendy and her team have secured strategic wins in recent years for clients across the life sciences industry. Some recent examples include:

  • Represented Mylan Pharmaceuticals Inc. in a successful appeal at the U.S. Court of Appeals affirming a decision by the Patent Trial and Appeal Board that held key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan in both the challenge before the PTAB and at the Federal Circuit.
  • Representing Azurity Pharmaceuticals in patent litigation against Alkem defending Azurity’s intellectual property related to its Zonisade® product. (District of Delaware)
  • Representing Bow River LLC in Hatch-Waxman patent litigation against Alembic defending Bow River’s intellectual property rights. (District of Delaware)
  • Representing Azurity Pharmaceuticals in patent litigation against Saba defending Azurity’s intellectual property related to its Edarbyclor® product. (District of Delaware)
  • Served as lead counsel for Impossible Foods in a patent infringement litigation alleging infringement of seven Impossible Foods patents covering manufacturing processes, ingredients, and finished products relating to plant-based food containing heme and Impossible’s innovative transgenic yeast used to manufacture that heme. Successfully represented Impossible Foods in defense of six inter partes review petitions before the Patent Trial and Appeal Board in 2022 and 2023. Defeated defendant’s motion to dismiss and motion to stay the district court litigation. The matter was closely watched as the first patent infringement case in the burgeoning foodtech industry. With trial approaching, the parties resolved the matter and released a joint statement that said: “This resolution affirms Impossible Foods’ category leadership and the strength of its product portfolio related to heme.”  
  • Secured a dismissal for Spruce Biosciences in declaratory judgement litigation related to treatments for congenital adrenal hyperplasia (CAH) in a suit filed by Neurocrine Biosciences. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation against Amneal defending Azurity’s intellectual property related to its Nymalize® product. The matter settled favorably prior to trial. (District of New Jersey)
  • Representing Sandoz Inc. in patent infringement litigation relating to Sandoz’s generic version of Esbriet®. (District of New Jersey)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s generic version of Trulance®. (Northern District of West Virginia)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s generic version of Cinvanti®. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Thyquidity® product. The matter settled favorably. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Eprontia® product. The matter settled favorably. (District of New Jersey)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Katerzia® product. The matter settled favorably on the eve of trial. (District of New Jersey)
  • Represented Mylan Pharmaceuticals Inc. in proceedings which limited where Hatch-Waxman Act patent suits over generic drugs can be filed, rejecting an argument that the suits are permitted wherever the generic product may one day be sold. Instead, the court ruled that suit can be brought only in locations that are related to the generics maker’s filing of an abbreviated new drug application (ANDA). The Federal Circuit issued a unanimous, precedential opinion and backed a federal judge’s ruling that tossed on venue grounds Valeant Pharmaceuticals and Kaken Pharmaceutical Co. Ltd.’s infringement case against our client over competing versions of an antifungal medication, Jublia.
  • Represented Azurity Pharmaceuticals in patent litigations defending Azurity’s intellectual property related to its Firvanq® product. (District of Delaware)
  • Represented Azurity Pharmaceuticals in patent litigations defending Azurity’s intellectual property related to its Epaned® ready-to-use product. (District of Delaware)
  • Represented Thorne Research, Inc. in a patent litigation involving accusations by ChromaDex, Inc. and the Trustees of Dartmouth College that certain Thorne nutritional supplement products infringed their patents. Secured dismissal following invalidation of the asserted patents.  (Southern District of New York)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s a generic version of Restasis®. Following bench trial, the court held all asserted patent claims invalid. (Eastern District of Texas)
  • Represented Azurity Pharmaceuticals in patent litigation defending Azurity’s intellectual property related to its Qbrelis® product. (District of Delaware and District of New Jersey)
  • Represented Azurity Pharmaceuticals in a Hatch-Waxman patent infringement litigation relating to Azurity’s generic version of Januvia® (sitagliptin). The case was dismissed. (District of Delaware)
  • Represented Silvergate Pharmaceuticals, Inc. in Hatch-Waxman litigation defending Silvergate’s intellectual property related to its Epaned Kit® powder for oral solution product. The matter concluded with favorable settlement. (District of Delaware)
  • Successfully defended Mylan Technologies, Inc. against a motion for restraining order/preliminary injunction involving a Mylan’s generic version of Minivelle®, a transdermal product, with the court’s written opinion holding in favor of Mylan client on case dispositive issues. (District of Delaware)
  • Represented Pfenex, a biotechnology company, in inter partes review (IPR) proceedings challenging vaccine production patents owned by GlaxoSmithKline Biologicals SA. Took and defended expert depositions and delivered oral arguments resulting in a favorable settlement on the eve of the issuance of a PTAB decision.
  • Represented NuVasive, Inc., a medical device manufacturer, in patent infringement litigation against a competitor that marketed devices accused of infringing NuVasive’s patents for its groundbreaking spine fusion device. (Southern District of California)
  • Represented Mylan Pharmaceuticals Inc. in a Hatch-Waxman patent infringement litigation relating to Mylan’s a generic version of Jevtana. Following bench trial, the court held the asserted claims of the later-expiring patent invalid. (District of New Jersey)

Select Speaking Engagements

  • Moderator, “Aligning Innovation, Regulation, and IP Protection,” Life Sciences Patent Network (LSPN) Fall Meeting, October 15, 2024
Insights

Select Speaking Engagements

  • Moderator, “Aligning Innovation, Regulation, and IP Protection,” Life Sciences Patent Network (LSPN) Fall Meeting, October 15, 2024
Focus Areas
  • Animal Health
  • Biotech
  • FoodTech and AgTech
  • Life Sciences
  • Litigation
  • Patent Litigation
Recent Insights
News Articles
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 500 Leading Global IP Lawyers Guide
On June 18, 2026, Lawdragon published the 2026 edition of its 500 Leading Global IP Lawyers guide, recognizing the leading attorneys that are protecting innovation, defending brand integrity, and leveraging the assets at the heart of their clients' businesses. Wilson Sonsini partners Wendy Devine, Jordan Jaffe, David Kramer, and James Yoon have been named to the 2026 guide.
Learn More
Alerts
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
Learn More
View All
Recent Events
Affiliated Programs
PBSS Workshop: Intellectual Property Strategies and Best Practices
Wilson Sonsini is proud to partner with the Pharmaceutical & BioScience Society (PBSS) to present a workshop on intellectual property strategies and best practices on Thursday, February 6 at the Crowne Plaza Foster City.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.